# NCT05891080 (NCT05891080)

> Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05891080
- Phase: PHASE2
- Status: NOT_YET_RECRUITING
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Conditions: Stage III Non-small Cell Lung Cancer
- Interventions: Toripalimab; JS004; Pemetrexed; Nab-paclitaxel; Carboplatin; Surgery
- Enrollment: 124
- Primary outcome: Pathologic complete response (PCR) rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05891080